Swiss National Bank
AVBP icon

Swiss National Bank’s ArriVent BioPharma AVBP Stock Holding History

Swiss National Bank’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
48,800
+8,800
+22% +$260K ﹤0.01% 2018
2026
Q1 		$923K Hold
40,000
– – ﹤0.01% 2182
2025
Q4 		$805K Buy
40,000
+4,500
+13% +$93.7K ﹤0.01% 2235
2025
Q3 		$655K Buy
35,500
+9,100
+34% +$179K ﹤0.01% 2268
2025
Q2 		$575K Hold
26,400
– – ﹤0.01% 2296
2025
Q1 		$488K Hold
26,400
– – ﹤0.01% 2341
2024
Q4 		$703K Buy
+26,400
New +$758K ﹤0.01% 2339

Other funds holding AVBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EFM
E Fund Management Guangzhou, China $4.46B AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swiss National Bank's AVBP Position: Q2 2026 in Review

Swiss National Bank increased its ArriVent BioPharma (AVBP) stake by 22% in Q2 2026, buying an estimated $260K and bringing the position to 48,800 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2018.

Swiss National Bank first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 58 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Swiss National Bank held 48,800 shares of ArriVent BioPharma worth $1.7M as of Q2 2026.
  • Swiss National Bank bought 8,800 ArriVent BioPharma shares in Q2 2026, an estimated $260K.
  • ArriVent BioPharma made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2018 holding.
  • Swiss National Bank first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 58 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.